About Fluidigm
Fluidigm is a company based in San Francisco (United States) founded in 1999. Fluidigm has raised $40.53 million across 10 funding rounds from investors including AllianceBernstein, European Union and Viking Global Investors. The company has 205 employees as of December 31, 2021. Fluidigm has completed 3 acquisitions, including ARCXIS, DVS Sciences and InstruNor. Fluidigm operates in a competitive market with competitors including Cepheid, Beckman Coulter, Blackrock Neurotech, Bruker and Complete Genomics, among others.
- Headquarter San Francisco, United States
- Employees 205 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fluidigm Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$40.53 M (USD)
in 10 rounds
-
Latest Funding Round
$250 M (USD), Post-IPO
Apr 01, 2022
-
Investors
AllianceBernstein
& 15 more
-
Employee Count
205
as on Dec 31, 2021
-
Investments & Acquisitions
ARCXIS
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Fluidigm
Unlock access to complete
Sales and Marketing
23 people
Software Development Team
16 people
Leadership Team
14 people
Finance and Accounting
11 people
Senior Team
7 people
Product Management Team
6 people
Creative and Marketing Team
3 people
Operations Team
2 people
Unlock access to complete
Funding Insights of Fluidigm
Fluidigm has successfully raised a total of $40.53M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fluidigm
Fluidigm has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include AllianceBernstein, European Union and Viking Global Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Sector-agnostic investments in late-stage startups are made by Cross Creek.
|
Locked | Locked | Locked |
Investor details for Fluidigm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fluidigm
Fluidigm has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include ARCXIS, DVS Sciences and InstruNor.
Investment portfolio details for Fluidigm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufacturer of cancer and immune system treatment devices
|
Locked | Locked | 2011 | Locked | |
|
Construction management services are offered to residential builders.
|
Locked | Locked | 2004 | Locked | |
|
Novel bioanalytical solutions are manufactured and distributed globally.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Fluidigm
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Fluidigm
Detailed financials for Fluidigm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fluidigm Comparisons
Peer comparison for Fluidigm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fluidigm
Fluidigm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Beckman Coulter, Blackrock Neurotech, Bruker and Complete Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Provider of products for biomedical testing for R&D, diagnostic and commercial applications
|
|
| Locked | Locked | Locked |
Medical devices for neurological therapies are developed.
|
|
| Locked | Locked | Locked |
Diversified research instrument systems are manufactured and supplied.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools
|
Detailed competitors of Fluidigm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fluidigm
Complete news archive for Fluidigm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fluidigm
Fluidigm was founded in 1999 and raised its 1st funding round 5 years after it was founded.
Fluidigm is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fluidigm is a funded company, having raised a total of $40.53M across 10 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Fluidigm is 205.
Fluidigm was founded in 1999 in San Francisco, United States, and operates within the life sciences sector. Instruments and platforms are provided for applications such as next-generation sequencing library preparation, single-cell PCR, genomics, epigenomics, and transcriptomics. Key products include the Access Array and Juno systems, Biomark HD and EP1 for genotyping assays, C1 for single-cell analysis, and Callisto for long-term cell culture experiments. Operations focus on biotechnology tools distributed globally.
Fluidigm's top competitors include Cepheid, Blackrock Neurotech and Agilent.
Fluidigm has made 3 acquisitions, including ARCXIS, DVS Sciences, and InstruNor.
Fluidigm has 16 investors. Key investors include AllianceBernstein, European Union, Viking Global Investors, Casdin Capital, and Cross Creek.